Hepatic hemangioma is a benign tumor of the liver originating from vascular endothelial cells, while hepatocellular carcinoma is a malignant tumor originating from the liver. Besides the difference in tumor nature, there are also differences between the two in terms of etiology, symptoms, examination, treatment and prognosis: 1. Etiology: the formation mechanism of hepatic hemangioma is still unclear, which may be due to congenital genetic defects or may be related to estrogen; the etiology of hepatocellular carcinoma, although still unclear, is related to carcinogenic mutations. Hepatitis virus infection, cirrhosis, certain hereditary metabolic diseases, aflatoxin, etc. are all risk factors of liver cancer; 2. Symptoms: most patients with hepatic hemangioma do not have any obvious symptoms; a few patients may experience pain in the right upper abdomen, abdominal distension, nausea, vomiting and other discomforts; patients with liver cancer may experience unexplained weight loss, loss of appetite, recurrent nausea and vomiting, skin itching, jaundice as the tumor increases; 3. Hepatocellular carcinoma can be diagnosed by imaging examinations such as ultrasound, CT and MRI; liver cancer can be diagnosed by imaging examinations such as dynamic enhanced MRI, dynamic enhanced CT, ultrasonography, selective hepatic arteriography and biopsy pathological examination; 4. . If the tumor is large in size or if there is persistent pain and discomfort, then surgical resection of hepatic hemangioma is required; the best treatment for hepatocellular carcinoma is surgical resection of the lesion or comprehensive treatment measures such as liver intervention combined with immunotherapy and targeted therapy. Surgical resection usually takes the form of partial hepatectomy, in addition, ablation therapy, embolization therapy, targeted therapy, immunotherapy, chemotherapy and radiotherapy can also be used; 5. Prognosis: patients with hepatic hemangioma have a better prognosis and can generally be cured; patients with hepatocellular carcinoma have a worse prognosis and the cure rate is not high. The 5-year survival rate of early stage hepatocellular carcinoma is 30%, once peripheral lymph node metastasis occurs, the 5-year survival rate is about 10%, and if distant metastasis occurs, the 5-year survival rate is about 2%.